IRVINE, Calif., June 15, 2011 /PRNewswire/ — Irvine
Pharmaceutical Services is pleased to announce the exciting
addition of Dr. Assad Al-Ammar to Irvine’s analytical management
team as the new Manager of Minerals. Dr. Al-Ammar brings with
him over 25 years of analytical experience. Dr.
Al-Ammar has over fourteen years of experience with ICP-MS
and has fifteen peer-reviewed research papers published in both the
United States and Europe. Additionally, Dr. Al-Ammar has
seven years experience with LC-ICP-MS and GC-ICP-MS speciation of
toxic and pharmaceutically important elements and fifteen years of
experience with ICP-AES, XRF, GC, and LC.
“With the upcoming changes to USP Chapter 231, Heavy Metals, Dr.
Al-Ammar is a terrific addition to our minerals group,” said Yvonne
Verburgt, Vice President of Business Development and Marketing.
“We believe his extensive expertise and experience with
ICP/ICP-MS methodology will even further strengthen the
department’s level of scientific leadership and serve as a
tremendous asset to our clients with the upcoming proposed new USP
General Chapters, Elemental Impurities 232 and 233.”
Dr. Al-Ammar holds a Ph.D. in Analytical Chemistry from
Glasgow University, United Kingdom, and was a postdoctoral fellow
at the University of Massachusetts.
Learn more about Irvine and the upcoming proposed USP General
Chapters, Elemental Impurities 232 and 233 at www.irvinepharma.com
or call us today at 877-445-6654.
About Irvine Pharmaceutical Services, Inc.
Irvine Pharmaceutical Services, Inc., along with its affiliate
Avrio Biopharma, is a
premier contract development and manufacturing organization
providing support to the pharmaceutical, biopharmaceutical, and
medical device industries. Irvine and Avrio together provide full
cGMP specialized product developmen
‘/>”/>
